Agilent Technologies, Wasatch BioLabs Collaborate on Native-Read Targeted Sequencing

MT Newswires Live12-20

Agilent Technologies (A) has entered into a co-marketing agreement with Wasatch BioLabs to accelerate the adoption of Wasatch's Direct Targeted Methylation Sequencing platform, Wasatch said Friday.

The collaboration combines Agilent's SureSelect for genomic DNA and Avida for cell-free DNA with Wasatch's native-read workflow to expand access to targeted sequencing and expedite the development of cost-efficient assays for research, according to a statement.

The companies will offer scientific information, educational programming, and technology demonstrations through 2027, Wasatch said.

Price: 138.15, Change: +1.25, Percent Change: +0.91

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment